{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:39:08Z","timestamp":1784302748774,"version":"3.55.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Hypothesis<\/jats:title>\n                    <jats:p>Antipsychotic use in severe mental illnesses (SMI) is associated with metabolic dysregulation, including antipsychotic-induced weight gain (AIWG), type 2 diabetes (T2D), and dyslipidemia. In the case of non-response to metformin which is currently recommended for AIWG mitigation, no clear alternatives exist. Semaglutide, a weekly injectable glucagon like peptide-1 receptor agonist, represents a promising option. However, effectiveness and safety data in SMI are lacking. With initiation of semaglutide, we hypothesized weight loss, improvements in metabolic indices, and good tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>A retrospective chart review was conducted for inpatients receiving antipsychotics, initiated on once-weekly subcutaneous semaglutide between January 4, 2018 and March 31, 2024 at the Centre for Addiction and Mental Health in Toronto, Canada, that analyzed weight loss, metabolic parameters, and side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Results<\/jats:title>\n                    <jats:p>47 individuals with SMI were included: 59.6% males, mean age of 43\u2009\u00b1\u200913.2\u00a0years, 83% had dysglycemia, and 66% had T2D at baseline. The maximum dose of semaglutide in this cohort was 2\u00a0mg\/week. There was a mean weight loss of 3.15\u2009\u00b1\u20090.77\u00a0kg (n\u2009=\u200947), 7.27\u2009\u00b1\u20090.97\u2009kg (n\u2009=\u200924), 9.33\u2009\u00b1\u20091.16\u2009kg (n\u2009=\u200915), and 12.25\u2009\u00b1\u20091.32\u2009kg (n\u2009=\u200911) at 3, 6, 9, and 12\u2009months, respectively (P\u2009&amp;lt;\u2009.001). Individuals without T2D experienced greater weight loss versus those with T2D (P\u2009=\u2009.022). Additionally, significant decreases were noted in body mass index and HbA1c (P\u2009&amp;lt;\u2009.001), alongside improvements in lipid parameters; most common side effects were gastrointestinal in nature but did not result in semaglutide discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This retrospective chart review of inpatients with SMI supports efficacy and safety of semaglutide up to a year of follow-up, warranting future adequately powered randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schbul\/sbaf236","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T13:17:01Z","timestamp":1764767821000},"source":"Crossref","is-referenced-by-count":1,"title":["The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients"],"prefix":"10.1093","volume":"52","author":[{"given":"Riddhita","family":"De","sequence":"first","affiliation":[{"name":"Complex Care and Recovery, Centre for Addiction and Mental Health (CAMH) , Toronto , ON, M6J 1H3,","place":["Canada"]},{"name":"Institute of Medical Science, University of Toronto , Toronto , ON, M5S 3K3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Amin Alfatwa","sequence":"additional","affiliation":[{"name":"Complex Care and Recovery, Centre for Addiction and Mental Health (CAMH) , Toronto , ON, M6J 1H3,","place":["Canada"]},{"name":"Department of Pharmacology & Toxicology, University of Toronto , Toronto , ON, M5S 3K3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pruntha","family":"Kanagasundaram","sequence":"additional","affiliation":[{"name":"Complex Care and Recovery, Centre for Addiction and Mental Health (CAMH) , Toronto , ON, M6J 1H3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Eve","family":"Saragosa","sequence":"additional","affiliation":[{"name":"Complex Care and Recovery, Centre for Addiction and Mental Health (CAMH) , Toronto , ON, M6J 1H3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Chan","sequence":"additional","affiliation":[{"name":"Complex Care and Recovery, Centre for Addiction and Mental Health (CAMH) , Toronto , ON, M6J 1H3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9433-9416","authenticated-orcid":false,"given":"Gary","family":"Remington","sequence":"additional","affiliation":[{"name":"Complex Care and Recovery, Centre for Addiction and Mental Health (CAMH) , Toronto , ON, M6J 1H3,","place":["Canada"]},{"name":"Institute of Medical Science, University of Toronto , Toronto , ON, M5S 3K3,","place":["Canada"]},{"name":"Department of Psychiatry, University of Toronto , Toronto , ON, M5T 1R8,","place":["Canada"]},{"name":"Banting and Best Diabetes Centre, University of Toronto , Toronto , ON, M5G 2C4,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Retnakaran","sequence":"additional","affiliation":[{"name":"Institute of Medical Science, University of Toronto , Toronto , ON, M5S 3K3,","place":["Canada"]},{"name":"Banting and Best Diabetes Centre, University of Toronto , Toronto , ON, M5G 2C4,","place":["Canada"]},{"name":"Division of Endocrinology, University of Toronto , Toronto , ON, M5S 3H2,","place":["Canada"]},{"name":"Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital , Toronto , ON, M5G 1X5,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Sanches","sequence":"additional","affiliation":[{"name":"Complex Care and Recovery, Centre for Addiction and Mental Health (CAMH) , Toronto , ON, M6J 1H3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Sockalingam","sequence":"additional","affiliation":[{"name":"Complex Care and Recovery, Centre for Addiction and Mental Health (CAMH) , Toronto , ON, M6J 1H3,","place":["Canada"]},{"name":"Department of Psychiatry, University of Toronto , Toronto , ON, M5T 1R8,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Mahavir","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Complex Care and Recovery, Centre for Addiction and Mental Health (CAMH) , Toronto , ON, M6J 1H3,","place":["Canada"]},{"name":"Institute of Medical Science, University of Toronto , Toronto , ON, M5S 3K3,","place":["Canada"]},{"name":"Department of Psychiatry, University of Toronto , Toronto , ON, M5T 1R8,","place":["Canada"]},{"name":"Banting and Best Diabetes Centre, University of Toronto , Toronto , ON, M5G 2C4,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret K","family":"Hahn","sequence":"additional","affiliation":[{"name":"Complex Care and Recovery, Centre for Addiction and Mental Health (CAMH) , Toronto , ON, M6J 1H3,","place":["Canada"]},{"name":"Institute of Medical Science, University of Toronto , Toronto , ON, M5S 3K3,","place":["Canada"]},{"name":"Department of Pharmacology & Toxicology, University of Toronto , Toronto , ON, M5S 3K3,","place":["Canada"]},{"name":"Department of Psychiatry, University of Toronto , Toronto , ON, M5T 1R8,","place":["Canada"]},{"name":"Banting and Best Diabetes Centre, University of Toronto , Toronto , ON, M5G 2C4,","place":["Canada"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Blegdamsvej 3B, 2200, Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"2026061513280216800_ref1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1463-1326.2009.01038.x","article-title":"Obesity, serious mental illness and antipsychotic drugs","volume":"11","author":"Holt","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2026061513280216800_ref2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1745-0179-2-14","article-title":"Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study","volume":"2","author":"De Hert","year":"2006","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"2026061513280216800_ref3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/oxfordjournals.schbul.a033504","article-title":"Prevalence and correlates of diabetes in National Schizophrenia Samples","volume":"26","author":"Dixon","year":"2000","journal-title":"Schizophr Bull"},{"key":"2026061513280216800_ref4","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.ahj.2005.02.007","article-title":"Schizophrenia and increased risks of cardiovascular disease","volume":"150","author":"Hennekens","year":"2005","journal-title":"Am Heart J"},{"key":"2026061513280216800_ref5","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1001\/jama.294.10.1255","article-title":"Trends in the leading causes of death in the United States, 1970-2002","volume":"294","author":"Jemal","year":"2005","journal-title":"JAMA."},{"key":"2026061513280216800_ref6","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"2026061513280216800_ref7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1017\/S003329171100105X","article-title":"Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices","volume":"42","author":"Mitchell","year":"2012","journal-title":"Psychol Med"},{"key":"2026061513280216800_ref8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1192\/bjp.bp.111.094532","article-title":"Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: meta-analysis","volume":"201","author":"Mitchell","year":"2012","journal-title":"Br J Psychiatry"},{"key":"2026061513280216800_ref9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1176\/appi.ps.56.3.273","article-title":"Defining and measuring clinical effectiveness in the treatment of schizophrenia","volume":"56","author":"Nasrallah","year":"2005","journal-title":"Psychiatr Serv"},{"key":"2026061513280216800_ref10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"2026061513280216800_ref11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/acps.13758","article-title":"The impact of weight gain on antipsychotic nonadherence or discontinuation: a systematic review and meta-analysis","volume":"151","author":"De","year":"2025","journal-title":"Acta Psychiatr Scand"},{"key":"2026061513280216800_ref12","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1002\/pcn5.13","article-title":"The pharmacological treatment of schizophrenia: how far have we come?","volume":"1","author":"Rubio","year":"2022","journal-title":"Psychiatry Clin Neurosci Rep"},{"key":"2026061513280216800_ref13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2174\/1574886314666190301152734","article-title":"Positive and negative effects of antipsychotic medication: an international online survey of 832 recipients","volume":"14","author":"Read","year":"2019","journal-title":"Curr Drug Saf"},{"key":"2026061513280216800_ref14","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbae205","article-title":"Metformin for the prevention of antipsychotic-induced weight gain: guideline development and consensus validation","volume":"51","author":"Carolan","journal-title":"Schizophr Bull."},{"key":"2026061513280216800_ref15","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1176\/appi.ajp.2013.12010127","article-title":"Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder","volume":"170","author":"Jarskog","year":"2013","journal-title":"Am J Psychiatry"},{"key":"2026061513280216800_ref16","doi-asserted-by":"publisher","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"CMAJ."},{"key":"2026061513280216800_ref17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41398-021-01338-2","article-title":"Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial","volume":"11","author":"Agarwal","year":"2021","journal-title":"Transl Psychiatry"},{"key":"2026061513280216800_ref18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/dom.13522","article-title":"Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis","volume":"21","author":"Siskind","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2026061513280216800_ref19","volume-title":"StatPearls","author":"Collins","year":"2024"},{"key":"2026061513280216800_ref20","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.18553\/jmcp.2018.24.9-a.s42","article-title":"Cardiovascular outcomes with once-weekly GLP-1 RAs: clinical and economic implications","volume":"24","author":"Heile","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"2026061513280216800_ref21","doi-asserted-by":"publisher","first-page":"e029282","DOI":"10.1161\/JAHA.122.029282","article-title":"Role of glucagon-like peptide-1 receptor agonists in achieving weight loss and improving cardiovascular outcomes in people with overweight and obesity","volume":"12","author":"Michos","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026061513280216800_ref22","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/dom.13167","article-title":"Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX)","volume":"20","author":"Siskind","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026061513280216800_ref23","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/dom.14334","article-title":"The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomized, double-blind, placebo-controlled trial","volume":"23","author":"Whicher","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2026061513280216800_ref24","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia Spectrum disorder","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"2026061513280216800_ref25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/dom.12795","article-title":"Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial","volume":"19","author":"Ish\u00f8y","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2026061513280216800_ref26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jad.2025.04.046","article-title":"A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults","volume":"382","author":"Patino","year":"2025","journal-title":"J Affect Disord"},{"key":"2026061513280216800_ref27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3390\/ph18030399","article-title":"Semaglutide as a GLP-1 agonist: a breakthrough in obesity treatment","volume":"18","author":"Salvador","year":"2025","journal-title":"Pharmaceuticals."},{"key":"2026061513280216800_ref28","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab"},{"key":"2026061513280216800_ref29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: a review","volume":"25","author":"Bergmann","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026061513280216800_ref30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.eclinm.2024.103020","article-title":"Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis","volume":"79","author":"Liu","year":"2025","journal-title":"eClinicalMedicine."},{"key":"2026061513280216800_ref31","volume-title":"ATCDDD\u2014ATC\/DDD Index 2025","author":"WHO Collaborating Centre for Drug Statistics Methodology"},{"key":"2026061513280216800_ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/oxfordjournals.schbul.a033302","article-title":"The co-investigators of the PORT project. Translating research into practice: the schizophrenia patient outcomes research team (PORT) treatment recommendations","volume":"24","author":"Lehman","year":"1998","journal-title":"Schizophr Bull"},{"key":"2026061513280216800_ref33","doi-asserted-by":"publisher","first-page":"20451253231165169","DOI":"10.1177\/20451253231165169","article-title":"Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin\u2014a case series","volume":"13","author":"Prasad","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"2026061513280216800_ref34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S2215-0366(25)00129-4","article-title":"Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia","volume":"12","author":"Siskind","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"2026061513280216800_ref35","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1001\/jamapsychiatry.2025.2332","article-title":"Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: the HISTORI randomized clinical trial","volume":"82","author":"Ganeshalingam","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"2026061513280216800_ref36","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026061513280216800_ref37","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"2026061513280216800_ref38","doi-asserted-by":"publisher","first-page":"e2231982","DOI":"10.1001\/jamanetworkopen.2022.31982","article-title":"Weight loss outcomes associated with Semaglutide treatment for patients with overweight or obesity","volume":"5","author":"Ghusn","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026061513280216800_ref39","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/dom.15386","article-title":"Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: an updated systematic review and meta-analysis including the 2-year STEP 5 trial","volume":"26","author":"Qin","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026061513280216800_ref40","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00592-022-01936-6","article-title":"Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes","volume":"59","author":"Di Folco","year":"2022","journal-title":"Acta Diabetol"},{"key":"2026061513280216800_ref41","doi-asserted-by":"publisher","first-page":"e015716","DOI":"10.1161\/JAHA.119.015716","article-title":"Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on endothelial glycocalyx, arterial function, and myocardial work index in patients with type 2 diabetes mellitus after 12-month treatment","volume":"9","author":"Ikonomidis","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026061513280216800_ref42","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1111\/dom.13353","article-title":"Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials","volume":"20","author":"Ahr\u00e9n","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026061513280216800_ref43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.15605\/jafes.037.02.14","article-title":"Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis","volume":"37","author":"Tan","year":"2022","journal-title":"J ASEAN Fed Endocr Soc"},{"key":"2026061513280216800_ref44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.33552\/OJCRR.2025.08.000683","article-title":"Unhealthy meals in hospitals: an ethical contradiction in cardiac care","volume":"8","author":"Mulijono","year":"2025","journal-title":"Online J Cardiol Res Rep"},{"key":"2026061513280216800_ref45","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/archinternmed.2012.2368","article-title":"Evaluation of sodium levels in hospital patient menus","volume":"172","author":"Arcand","year":"2012","journal-title":"Arch Intern Med"},{"key":"2026061513280216800_ref46","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/YCO.0000000000000952","article-title":"GLP-1 receptor agonists and weight loss in schizophrenia - past, present, and future","volume":"37","author":"Trott","year":"2024","journal-title":"Curr Opin Psychiatry"}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/3\/sbaf236\/68529598\/sbaf236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/3\/sbaf236\/68529598\/sbaf236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:28:10Z","timestamp":1781544490000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/doi\/10.1093\/schbul\/sbaf236\/8708284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,15]]},"published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbaf236","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,10]]},"article-number":"sbaf236"}}